Indefinite Delivery Contract 75N93022D00004
Award Date
12/1/21
Last Date to Order
11/30/28
Federal Agency
National Institute of Allergy and Infectious Diseases
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Pricing Type
Cost Plus Fixed Fee
Legislative Mandate
Employment Eligibility Verification
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to support preclinical and translational vaccine development services for HIV vaccines and other candidate agents. The total potential value of the contracts is $364,553,934 over a seven-year period of performance from December 2021 through November 2028. The contracts will provide a broad range of capabilities required for preclinical and...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts totaling approximately $364.5 million to support preclinical and translational vaccine development services. Task areas include product storage and shipping, safety and immunogenicity studies, feasibility assessments, analytical development, process development, cGMP manufacturing, stability testing, fill-finish, and scientific support. Task...
The National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health within the Department of Health and Human Services, awarded multiple Indefinite Delivery/Indefinite Quantity contracts valued collectively up to $364.5 million to support preclinical and translational vaccine development services for HIV vaccines and other candidate agents. The ordering period is from December 2021 through November 2028. Under the contracts, the prime contractors will...
This is an Indefinite Delivery Contract (IDC) awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Technical Resources International, Inc. (Technical Resources Intl), a minority-owned, woman-owned, Hispanic American-owned small business. The contract supports a broad range of preclinical and translational development services for promising vaccines and related products for HIV and other candidate agents, with a...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts with a total potential value of $364,553,934 to support preclinical and translational vaccine development services. Task areas under the contracts include product storage and shipping, safety and immunogenicity studies, feasibility assessments, analytical development, process development, cGMP manufacturing, stability testing, fill-finish, and...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products addressing HIV, HBV, HCV, and Mycobacterium tuberculosis. The total potential value of the IDV is $107,274,471 over seven years ending October 2027. Task orders have been issued under several areas. Lovelace Biomedical Research Institute received a $18,397 order to develop...
This indefinite delivery contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to provide preclinical development support for candidate products addressing HIV, HBV, HCV and other infectious diseases. The multiple award ID/IQ contract holds a potential value of $107 million and a period of performance from October 2020 through October 2027. The contract establishes seven task areas for procuring services such as in vitro testing,...
The National Institute of Allergy and Infectious Diseases has awarded an indefinite delivery contract with a potential value of $107,274,471 to multiple prime contractors to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. Task orders will be issued under seven task areas, including in vitro testing, synthesis of therapeutic agents, small animal...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a single award indefinite delivery contract to International Aids Vaccine Initiative Inc. to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. The potential value of the contract is $30 million with a performance period from January 2023 through September 2030. Services will be delivered under five task areas: product...
The National Institute of Allergy and Infectious Diseases awarded multiple indefinite delivery/indefinite quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. The scope of work encompasses seven task areas: in vitro testing, synthesis of therapeutic agents, small animal models for HIV/HBV/HCV and mycobacterium, formulation...